C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Result of AGM
24 January 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that at its Annual General Meeting, held today at 11.00 am, all resolutions were duly passed.
- Ends -
Contacts
| C4X Discovery Holdings |
|
| Mo Noonan, Communications | +44 (0)787 6444977 |
| | |
| Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
| Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
| Rupert Dearden (Corporate Broking) | |
|
|
|
| C4X Discovery Media - Consilium Strategic Communications |
|
| Mary-Jane Elliott, Chris Gardner, Matthew Neal | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have three commercially partnered programmes with one candidate in clinical development.
We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio. For further information see www.c4xdiscovery.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.